Efficacy of XXXX and @entity786 combination for recurrent and metastatic carcinoma of the uterine cervix.

@entity1 @entity3432 @entity137 @entity417 @entity882 @entity900 @entity786 @entity189 @entity204 @entity1210
The efficacy of a combination of @entity786 and @entity900 in @entity1 with metastatic and recurrent @entity189 , was tested. Thirty @entity1 were included in the study. Initially, 27 @entity1 (90%) had received pelvic radiation and intracavitary boost and one @entity1 was additionally given paraaortic radiation. @entity900 was given at 75 mg/m2 followed by @entity786 at 750 mg/m2 on day 1 with three weekly intervals for a maximum of six cycles. All @entity1 received a median of four cycles of chemotherapy. The overall response rate for all eligible @entity1 was 20% (continuous @entity3432 , PR: 4 @entity1 ). Overall response rate and progressive response in @entity1 with relapse within the previous radiation field were 9.5% and 66.7%, respectively; while for @entity1 who had recurrent disease outside any irradiated area both were 44.4%. Eighteen @entity1 (60%) had early withdrawal from the planned schedule, which was due to @entity1 incompliance in seven @entity1 (23.3%), disease progression in ten (33.3%) and @entity204 after the first cycle in one @entity1 (3.3%). @entity417 was the most frequent @entity137 , necessiating 24 transfusions in nine @entity1 (30%). WHO grade 3 and 4 @entity137 were @entity417 : 13 (43.3%), @entity1210 : one (3.3%), @entity882 : two (6.6%), renal: one, emesis: nine (30.0%) @entity1 . The median survival duration for all eligible @entity1 was 11 months. Univariate analysis revealed that progressive response to chemotherapy was the only prognostic factor for survival (7.1 vs 16.8 months, p = 0.003). The combination of @entity900 and @entity786 did not appear to be more active than single agent @entity900 in this @entity1 group with a relatively poor prognosis. Further studies are required to determine a better therapeutic approach for @entity1 with relapsed @entity189 .
